Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Benjamin Kearns, Katy Cooper, Anna Cantrell & Chloe Thomas. (2021) Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. Neuropsychiatric Disease and Treatment 17, pages 125-137.
Read now
Read now
Ben F.M. Wijnen, Frederick W. Thielen, Steef Konings, Talitha Feenstra, Mark Van Der Gaag, Wim Veling, Lieuwe De Haan, Helga Ising, Mickaël Hiligsmann, Silvia M.A.A. Evers, Filip Smit & Joran Lokkerbol. (2020) Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. Expert Review of Pharmacoeconomics & Outcomes Research 20:3, pages 269-279.
Read now
Read now
Nicola Germain, Steven Kymes, Elin Löf, Anna Jakubowska, Clément François & James Weatherall. (2019) A systematic literature review identifying associations between outcomes and quality of life (QoL) or healthcare resource utilization (HCRU) in schizophrenia. Journal of Medical Economics 22:5, pages 403-413.
Read now
Read now
Myrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, Christophe Sapin, Amy M Duhig & Leslie Citrome. (2018) Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and Outcomes Research 10, pages 443-456.
Read now
Read now
Articles from other publishers (8)
Jia Liu, Lidan Cao & Jing Wu. (2022) Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China. Frontiers in Public Health 10.
Crossref
Crossref
Iara Carolina Barbosa Henrique, Tácio Lima, Daniela Oliveira Melo & Patricia Melo Aguiar. (2019) Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 1-15.
Crossref
Crossref
Aleksandra Dutina & Ivana Stašević-Karličić. (2018) Pharmacoeconomic aspects of schizophrenia. Racionalna terapija 10:1, pages 37-41.
Crossref
Crossref
Liang Lin, Ying J. Zhao, Hui J. Zhou, Ai L. Khoo, Monica Teng, Lay B. Soh, Boon P. Lim & Kang Sim. (2016) Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. International Clinical Psychopharmacology 31:2, pages 84-92.
Crossref
Crossref
Anne Karow, Monika Bullinger & Martin Lambert. 2016. Beyond Assessment of Quality of Life in Schizophrenia. Beyond Assessment of Quality of Life in Schizophrenia
123
144
.
Charon Lessing, Toni Ashton & Peter Davis. (2014) Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment. Administration and Policy in Mental Health and Mental Health Services Research 42:6, pages 695-703.
Crossref
Crossref
Krithika Rajagopalan, Shien Guo, Luis Hernandez, Julia Green & Antony Loebel. (2014) Clinical and Cost Consequences of Metabolic Effects of Lurasidone Versus
Other Atypical Antipsychotics in Schizophrenia. Open Medicine Journal 1:1, pages 1-9.
Crossref
Crossref
Mark D Brennan. (2014) Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 15:6, pages 869-884.
Crossref
Crossref